N
PGNX

Natixis’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Natixis’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-17,463
Closed -$112K – 1009
2017
Q4 		$112K Buy
17,463
+2,463
+16% +$15K ﹤0.01% 805
2017
Q3 		$110K Buy
+15,000
New +$95.3K ﹤0.01% 1180

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Natixis's PGNX Position: Q1 2018 in Review

Natixis sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 17,463 shares — an estimated $112K sold.

Natixis first reported a position in PGNX in Q3 2017 and held it in 2 quarters. The position peaked at $112K in Q4 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

  • Natixis reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Natixis sold 17,463 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $112K.
  • Natixis first reported a position in Progenics Pharmaceuticals Inc in Q3 2017 and held it in 2 quarters.
  • Natixis's Progenics Pharmaceuticals Inc position peaked at $112K in Q4 2017.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on Natixis's 13F filing for Q1 2018, filed 15 May 2018.